Alzheimer's disease (AD) is a neurodegenerative pathology characterized by aggregates of amyloid-b (Ab) and phosphorylated tau protein, synaptic dysfunction, and spatial memory impairment. The Wnt signaling pathway has several key functions in the adult brain and has been associated with AD, mainly as a neuroprotective factor against Ab toxicity and tau phosphorylation. However, dysfunction of Wnt/b-catenin signaling might also play a role in the onset and development of the disease. J20 APPswInd transgenic (Tg) mouse model of AD was treated i.p. with various Wnt signaling inhibitors for 10 weeks during presymptomatic stages. Then, cognitive, biochemical and histochemical analyses were performed. Wnt signaling inhibitors induced severe changes in the hippocampus, including alterations in Wnt pathway components and loss of Wnt signaling function, severe cognitive deficits, increased tau phosphorylation and Ab 1-42 peptide levels, decreased Ab42/Ab40 ratio and Ab 1-42 concentration in the cerebral spinal fluid, and high levels of soluble Ab species and synaptotoxic oligomers in the hippocampus, together with changes in the amount and size of senile plaques. More important, we also observed severe alterations in treated wild-type (WT) mice, including behavioral impairment, tau phosphorylation, increased Ab 1-42 in the hippocampus, decreased Ab 1-42 in the cerebral spinal fluid, and hippocampal dysfunction. Wnt inhibition accelerated the development of the pathology in a Tg AD mouse model and contributed to the development of Alzheimer's-like changes in WT mice. These results indicate that Wnt signaling plays important roles in the structure and function of the adult hippocampus and suggest that inhibition of the Wnt signaling pathway is an important factor in the pathogenesis of AD.
of AD cases increase dramatically as the population ages (Qiu et al. 2009 ). Although the signs and symptoms, risk factors (Richardson et al. 2014) and some neuroprotective agents of this disease (Longo and Massa 2004; Rios et al. 2014) are known, the causes remain unclear. According to the amyloid cascade hypothesis, the neurodegenerative process begins with the formation of the amyloid-b (Ab) peptide (Hardy 2006; Barage and Sonawane 2015; Musiek and Holtzman 2015) . Ab is produced by the sequential cleavage of amyloid precursor protein (APP) by the b-and c-secretase enzymes (De Strooper et al. 2010) , followed by the formation of oligomers (Walsh et al. 2002; Yoshiike et al. 2003; Shankar et al. 2007 Shankar et al. , 2008 , and finally the appearance of SPs (Mucke and Selkoe 2012) . Ab also deregulates kinases, phosphatases, and diverse signaling pathways that trigger the phosphorylation of the tau protein to produce NFTs and neuronal dysfunction (Mucke and Selkoe 2012) .
The Wnt signaling pathway regulates synaptic transmission and plasticity in the adult brain VarelaNallar 2014, 2015) . The canonical Wnt pathway is activated when the Wnt ligand binds to the Frizzled (Fz) receptor and low-density lipoprotein receptor-related protein-5/6 (LRP5/6) co-receptor; the destruction complex formed by axin, glycogen synthase kinase (GSK)-3b, and adenomatous polyposis coli is then disassembled and induces the accumulation and subsequent translocation of b-catenin to the nucleus, where it associates with transcriptional factors, T-cell factor (TCF) and lymphoid enhancer factor (LEF), to activate the transcription of Wnt target genes (Jamieson et al. 2012) . In the absence of the ligand; b-catenin is phosphorylated by GSK-3b (McManus et al. 2005) and degraded by the proteasome, preventing the transcription of target genes (Aberle et al. 1997; Liu et al. 2002; Metcalfe and Bienz 2011) . A relationship between Wnt signaling and AD has been described (De Ferrari et al. 2014; Inestrosa and VarelaNallar 2014; Wan et al. 2014) . Studies have suggested that the loss of Wnt signaling plays an important role in the etiology of both familial AD (FAD) and sporadic AD. Mutations in presenilin 1, a component of the c-secretase, favor GSK-3b activity, tau hyperphosphorylation (Takashima et al. 1998) , b-catenin degradation (Zhang et al. 1998) and impede the transcriptional activities of cAMPresponse element binding protein-binding protein and p300 necessary to induce the transcription of Wnt target genes (Francis et al. 2006) . Deletion of the Lrp6 gene in a mouse model of AD also exacerbates amyloid deposition , suggesting that Wnt signaling dysfunction is a possible mechanism by which FAD mutations lead to the early development and rapid progression of AD (Baki et al. 2004) . Furthermore, a polymorphism in the promoter of GSK-3 that increases its activity is a risk factor for lateonset AD (Mateo et al. 2006) , and an allele of low-density lipoprotein receptor-related protein-6 (LRP6) associated with a loss of function of Wnt signaling is a susceptibility gene for late-onset AD (De Ferrari et al. 2007 ). Interestingly, chronic lithium treatment reduces the prevalence of AD, suggesting that activation of the Wnt signaling might inhibit processes critical to the initiation and development of AD (Forlenza et al. 2012) . Wnt plays a role in the Ab formation (Sun et al. 2002; Ryder et al. 2003; Su et al. 2004; Parr et al. 2015) . We have demonstrated that inhibition of the Wnt pathway increases Ab 42 levels and the Ab42/Ab40 ratio, favoring the formation of Ab oligomers in vitro (Tapia-Rojas et al. 2016) . Similarly, dysfunctional Wnt signaling induces tau phosphorylation mediated by GSK-3b (Scali et al. 2006; Hooper et al. 2008) . GSK-3b transgenic mice exhibit decreased nuclear b-catenin levels and tau hyperphosphorylation (Lucas et al. 2001) , and lithium treatment prevents the formation of NFTs (Engel et al. 2006) , suggesting that a loss of Wnt signaling participates in the appearance of both hallmarks of AD. Synaptic dysfunction is an early event in AD. An increase in the Wnt antagonist Dickkopf-related protein (Dkk)-1 is required to generate the synaptic loss mediated by Ab (Purro et al. 2012) . The suppression of Wnt signaling affects long-term potentiation (LTP), a neurophysiological correlate of learning and memory . Spatial learning increases the levels of the Wnt ligands in the hippocampus (Tabatadze et al. 2012) , and promotes the expression of genes involved in LTP and memory (Bourtchuladze et al. 1994; Kasahara et al. 2001) . Finally, the canonical Wnt pathway is required for recognition memory (Fortress et al. 2013) , which is affected in AD. Therefore, we hypothesize that the loss of canonical Wnt signaling is an important factor in the pathogenesis of AD.
In the present work, J20 APPswInd Tg AD mice were treated with different inhibitors of the Wnt pathway for 10 weeks during the pre-symptomatic stages. Wnt signaling dysfunction (i) induced a loss of spatial and recognition memory, (ii) triggered tau phosphorylation, (iii) increased Ab 1-42 levels and the Ab 42 /Ab 40 ratio in the hippocampus together with a reduction in the Ab 1-42 concentration in the cerebrospinal fluid (CSF), (iv) increased the levels of total Ab and soluble oligomers in the hippocampus, and (v) increased the area and size of SPs. Interestingly, we also observed a dysfunction in Wnt signaling in treated wild-type (WT) mice, which triggered impairments in learning and memory, phosphorylation of tau protein, and increased production of Ab 1-42 in the hippocampus. Taken together, our results indicate that dysfunctional Wnt signaling accelerates the development of AD in the J20 APPswInd Tg mouse model and induces AD-like neuropathological hallmarks in WT mice, suggesting that the loss of Wnt signaling may be a triggering factor for AD pathogenesis.
Materials and methods
Reagents and antibodies ICG-001 (Catalog Number 2275) was obtained from BioVision Inc. (Milpitas, CA, USA), and XAV939 (Catalog Number X3004) and IWP-2 (Catalog Number I0536) were obtained from Sigma Chemical Company (St. Louis, MO, USA). The primary antibodies used were mouse anti-b-actin clone AC-15 (A1978; Sigma-Aldrich, St. Louis, MO, USA), monoclonal anti-a-tubulin antibody (T5168; Sigma-Aldrich), rabbit anti-GSK-3b pSer-9 (#9336S; Cell Signaling Technology, Beverly, MA, USA), total GSK-3b (sc-9166; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-b-catenin (H-102) (sc-7199; Santa Cruz Biotechnology), anti-amyloid b antibody clone W0-2 (MABN10; Millipore Corporation, Bedford, MA, USA), rabbit anti-b-amyloid precursor protein (Catalog Number 51-2700; Invitrogen, Carlsbad, CA, USA) and anti-amyloid b antibody 6E10 (COVANCE, Princeton, New Jersey, USA).
Animals and treatments
Three-month-old male APPSwInd Tg mice expressing a mutant form of human APP bearing both the Swedish (K670N/M671L) and Indiana (V717F) mutations (APPSwInd) were obtained from The Jackson Laboratory (Stock no 004462; Bar Harbor, ME, USA) RRID: MMRRC_034829-JAX. This mouse model of AD is known commonly as J20. Animals were maintained at the Animal Facility of the Pontificia Universidad Cat olica de Chile under sanitary barrier in ventilated racks and in closed colonies. Experimental procedures were approved by the Bioethical and Biosafety Committee of the Faculty of Biological Sciences of the university. A total of eight animals per group were treated and handled according to the National Institutes of Health guidelines (NIH, Baltimore, MD, USA). To allocate mice to the different cages we used simple randomization. We assign subjects of random manner into three groups for Tg mice and four groups for WT mice. Intraperitoneal (IP) injections of ICG001 (60 mg/kg), XAV939 (0.1 mg/kg) or IWP2 (0.3 mg/kg) with saline solution as the vehicle were administered three times per week. Tg and WT control animals were only injected with vehicle. No blinding was performed in the treatment and posterior analyses. Both WT and Tg animals were treated for 10 weeks beginning at 3 months of age. In the Tg mice, this age is considered a pre-symptomatic stage because it precedes the deposition of senile plaque deposits (Mucke et al. 2000) and the signs of deficits in spatial memory and learning (Palop et al. 2003) .
In addition, we monitored the animals' body weights, as shown in Figure S1 . The mean weight of Tg control, XAV939-, and ICG001-treated mice group was 24.75 AE 1.359; 24.24 AE 1.162; and 26.14 AE 0.869, respectively. WT mice showed a mean weight of 22.78 AE 0.458 to control group; 22.72 AE 0.733 to ICGG001-treated group; 23.48 AE 0.713 to XAV939-treated group; and 21.87 AE 0.714 to IWP2-treated group. To further analyze the health of the mice, lipid and hepatic parameters were measured at the end of the treatment period. No significant differences were observed between the control and treated groups (Table S1 ). The inclusion/exclusion criteria for this study were the health of the animals after treatment. All the animals that finish correctly the treatment and remain healthy were used to continue the analysis. The animals that showed sign of illness were excluded. For this inclusion/exclusion criterion we evaluated the weight of the animals, the lipid and hepatic parameters and the visual inspection. Also, this study was not pre-registered.
Behavioral tests

Morris water maze tests
The Morris water maze (MWM) task was performed as previously described by our laboratory (Serrano et al. 2014; Tapia-Rojas et al. 2015b) . Briefly, the mice were trained in a 1.2-m-diameter circular pool (opaque water, 50 cm deep) filled with 19-21°C water. A submerged 9-cm platform (1 cm below the surface of water, invisible to the animal) was used for training, with a maximum trial duration of 60 s; the mice remained on the platform for 10 s at the end of each trial. Each animal was trained to locate the platform. The test was performed with three trials per day, and swimming was monitored using an automatic tracking system (HVS Imagen, Hampton, UK) to measure the latency time required to reach the platform and the time spent in each quadrant. After testing, the mouse was gently removed from the maze and returned to its cage.
Open field tests Open field (OF) tests were performed 2 days after the MWM test as previously described (Tapia-Rojas et al. 2015b) . The animals were individually placed at the center of a 72 9 72 9 32 cm white acrylic box and allowed to freely move within it for 10 min. For all behavioral tests, the data were gathered and analyzed with a video tracking system (HVS Imagen). Room temperature was maintained at 20°C.
Novel object recognition tests
Novel object recognition (NOR) tests were performed in a 38 9 38 9 32 cm white acrylic box 1 day after the OF test as previously described (Vargas et al. 2014; Tapia-Rojas et al. 2015b) . The animals were habituated to the box for two consecutive days, without objects present. For testing, each animal was placed at the center of the box containing two identical objects (old objects) for 10 min. Then, the box and objects were cleaned with a 50% methanol solution. Later, the animal was (after 2 h) exposed to one of the old objects and a new object of a different shape and color than the old object, and the box and objects were cleaned again to continue with the next animal. The recognition index was calculated as the time spent exploring the new object divided by the time spent exploring both objects.
Thioflavin-S staining Thioflavin-S staining was developed on gelatin-coated slices as previously described (Carvajal et al. 2013; Tapia-Rojas et al. 2015a) . After dehydration and rehydration in a graded series of ethanol and xylol, the slices were incubated in distilled water for 10 min and then immersed in the Th-S solution (0.1% Th-S in 70% ethanol) for 5 min. Then, the slices were washed twice in 70% ethanol for 30 s, and cover slips were placed using antifade mounting medium in the dark. Images of the stained brain sections were photographed using an Olympus BX51 microscope coupled to a MicroPublisher 3.3 RTV camera (QImaging, Surrey, BC, Canada). The luminescence of the incident light and the time of exposure were calibrated to assign pixel values ranging from 0 to 255 to RGB images (no light to full-light transmission), which were used for all preparations. The images were loaded into ImageJ v.1.40 g software (NIH) for analysis. The areas for measurement were selected by manually adjusting the threshold or by direct, manual selection of regions of interest in heterogeneously stained sections.
Image analysis
The stained brain sections were photographed using an Olympus BX51 microscope coupled to a Micro-publisher 3.3 RTV camera (QImaging). The luminescence of the incident light and the time of exposure were calibrated to assign pixel values ranging from 0 to 255 in the RGB image (no-light to full-light transmission), which were used for all preparations. The images were loaded into ImageJ v.1.40 g software (NIH) for analysis. The areas for measurement were selected by manually adjusting the threshold or by direct, manual selection of regions of interest in heterogeneously stained sections.
Immunoblotting
The hippocampus and cortex of the treated or control Tg mice were dissected on ice and immediately processed as previously described (Serrano et al. 2014; Tapia-Rojas et al. 2015c) . Briefly, the hippocampal and cortical tissues were homogenized in Radioimmunoprecipitation assay buffer (10 mM Tris-Cl, pH 7.4, EDTA 5 mM, 1% NP-40, 1% sodium deoxycholate, and 1% sodium dodecyl sulfate) supplemented with a protease inhibitor mixture and phosphatase inhibitors (25 mM NaF, 100 mM Na 3 VO 4 , and 30 lM Na 4 P 2 O 7 ) using a Potter homogenizer and then sequentially passed through syringes of different calibers. The protein samples were centrifuged twice at 15 000 g for 15 min at 4°C. The protein concentrations were determined using the bicinchoninic acid Protein Assay Kit (Pierce, Rockford, IL, USA). The samples were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by immunoblotting on polyvinylidene difluoride membranes.
Collection of CSF from the cisterna magna After the cognitive tests, CSF was extracted from the animals, and then the animals were killed for biochemical and histochemical analyses. All surgical instruments were disinfected with 70% ethyl alcohol before each use. To obtain CSF, the mice were anesthetized by IP injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). The anesthetized mice were then mounted in a stereotaxic device, and a 30-G needle attached to 1-mL syringe was carefully inserted into the dura mater. CSF was aspirated by pulling back the syringe plunger. CSF was ejected into a 0.2-mL Eppendorf tube and frozen at À150°C. The volume of CSF obtained from each animal was at least 5 lL without blood contamination (Liu and Duff 2008; Pegg et al. 2010) .
Determination of Ab peptide levels
To determine the concentrations of the Ab peptides, specific sandwich enzyme-linked immunosorbent assays (ELISAs) for Ab 1-40 and Ab 1-42 were used as previously described (EZBRAIN40, EZBRAIN42; EMD Millipore Corporation, Billerica, MA, USA) (Mufson et al. 2012; Cavieres et al. 2015; Tapia-Rojas et al. 2015b) . One hundred micrograms of total homogenized protein from the hippocampus or cerebrospinal fluid (CSF) was used to measure Ab 1-40 and Ab 1-42 levels according to the manufacturer's instructions. The plates were read at 450 nm and 590 nm on a Metertech 960 ELISA Analyzer.
Slot blot
Slot-blot assays were performed as previously described (Toledo and Inestrosa 2010; Serrano et al. 2014) . Briefly, the total protein extracts were centrifuged at 20 000 g for 1 h to eliminate fibrillar aggregates. The protein concentration in the soluble fraction was determined, and 6 lg of protein was spotted on a 0.45-lm 2 nitrocellulose membrane (Millipore), followed by blocking with 0.4% PBS-Tween-20 (PBS-T) gelatin and incubation with the antioligomeric A11 antibody (1/5000) for 2 h at 4°C. The slot blots were analyzed using the same methodology used for immunoblotting.
Statistical analysis
The data are expressed as the mean AE SEM of the experiments, with the number of experiments indicated in the corresponding figures. The data were statistically evaluated using Student's t-test with Dunnett's post hoc test or ANOVA followed by Bonferroni's post hoc test to determine the differences between more than two groups. p < 0.05 was considered statistically significant. All statistical analyses were performed using Prism software (GraphPad Software Inc., San Diego, CA, USA). Not statistical methods were used to predetermine the sample size.
Results
Treatment with Wnt signaling inhibitors alters the levels of key components of the Wnt pathway and its function Three-month-old J20 APPswInd Tg mice (pre-symptomatic stages, see methods) were treated with vehicle; ICG001, a small-molecule antagonist of b-catenin/TCF-mediated transcription (Emami et al. 2004 ) that we refer to hereafter 'transcription inhibitor' (TI); or XAV939, which inhibits the tankyrase enzyme and stabilizes axin in the destruction complex, referred to as 'axin stabilizer' (AS) (Huang et al. 2009 ). The treatments were administered by IP injection three times per week for 10 weeks. Animal health was monitored during treatment, including weekly recording of body weight ( Figure S1 ), and biochemical analysis of the blood was performed after the treatment was completed (Table S1 ). No significant differences in animal health parameters were observed between the control and treated mice.
After completion of the treatment, the animals were killed, and the brains were collected for biochemical analysis. Total proteins were obtained from the hippocampus, and western blots were performed. We measured the levels of different key components of the Wnt signaling pathway and Wnt target genes to evaluate the function of the Wnt signaling pathway. GSK-3b was active in the treated J20 Tg (Fig. 1a ) mice, as indicated by the increase in the levels of phosphoTyr216, an auto-phosphorylation site that increases kinase activity (Cole et al. 2004) . Casein kinase 1 phosphorylates bcatenin at Ser45 (Amit et al. 2002) , which primes b-catenin for subsequent phosphorylation by GSK-3b (Liu et al. 2002) at Ser33, Ser37, and Thr41 (Yost et al. 1996) , favoring its degradation via the proteasome (Liu et al. 2002) . Significant increases in phospho-b-catenin protein levels were observed in all treated groups (Fig. 1a) . Wnt signaling culminates with the translocation of b-catenin to the nucleus, where it activates TCF/LEF transcription factors, resulting in transcriptional activation of Wnt target genes (Jamieson et al. 2012) . To determine whether Wnt pathway function was intact, we evaluated the levels of two different Wnt target genes, c-jun (Mann et al. 1999 ) and cyclin-D1 (Shtutman et al. 1999; Tetsu and McCormick 1999) . The levels of both target genes of the Wnt pathway were decreased in J20 Tg mice (Fig. 1b) following treatment. In addition, we evaluated the levels of other important components of Wnt signaling that are not associated with Wnt target genes, such as the Wnt-7a, Wnt-3a, and Wnt-5a ligands, as well as, the Wnt antagonists Dkk-1, secreted frizzled-related protein (sFRP)-1 and sFRP-2. The levels of Wnt-7a and Wnt-3a, two canonical Wnt ligands, but not the non-canonical Wnt ligand, Wnt-5a, were decreased in the treated Tg mice (Fig. 1c) . In addition, the levels of Dkk-1, a canonical Wnt antagonist (Fedi et al. 1999) , were significantly increased in the treated Tg mice, as were the levels of sFRP-1 (Fig. 1d) . In contrast, the levels of sFRP-2, a Wnt inhibitor with affinity for the non-canonical ligand Wnt-5a (Varela-Nallar et al. 2010), were significantly decreased in Tg mice (Fig. 1d) . Taken together, these results indicate that treatment with two different Wnt inhibitors induced alterations in key components of the canonical Wnt pathway and strongly suggest that canonical Wnt signaling was dysfunctional or attenuated in the treated Tg APPswInd mice.
Alterations in Wnt function induce a loss of spatial and recognition memory in J20 Tg mice Wnt signaling plays important roles in hippocampal plasticity and has been proposed to regulate hippocampal learning and memory. Spatial learning in the MWM task has been shown to increase the levels of the Wnt7a/b and Wnt5a ligands in the rat hippocampus (Tabatadze et al. 2012) , and canonical Wnt signaling is necessary for hippocampal memory consolidation (Fortress et al. 2013) . In addition, progressive declines in learning and memory are important characteristics of AD, a neurodegenerative disease in which Wnt Signaling is decreased Inestrosa and Varela-Nallar 2014) . To evaluate whether dysfunction of Wnt signaling affects cognitive abilities and hippocampal function in J20 Tg mice, we subjected the control and treated animals to different tasks, including the MWM and the NOR test. In the MWM task, the mice were required to learn the location of a hidden platform using external cues. The escape latency values of the treated Tg mice were significantly higher than those of control animals ( Fig. 2a) . However, no significant differences in swimming speed were observed between the experimental groups, eliminating the possibility of treatment-induced alterations of locomotor activity (Table S2 ). The differences in escape latency between the control and treated J20 Tg animals on the different days of training are reflected in the swim tracks shown in Fig. 2 (b). These differences were significant during the first and second weeks of training, suggesting impairments in short-and longterm memory. To validate that the effects observed in the MWM were associated with spatial memory impairment and not deficient escape motivation or impairments of vision and/ or motor skills, we performed the visible platform version of the MWM test (D'Hooge and De Deyn 2001). The platform location was indicated by a marker rising above the water, and all animals were trained until they found the platform. Ten minutes later, the control and treated mice were placed in the pool, and the escape latency was evaluated. No significant differences in latency were observed between the control and treated animals ( Fig. 2c) , indicating that the observed results were dependent on hippocampal function. We performed an OF test to eliminate the possibility that anxious behavior developed as a consequence of treatment. As shown in Figure S2 , the treated animals did not exhibit any significant differences in the distance traveled (Figure Figure S2g and h) compared with those of the control animals, confirming that the treated animals did not present anxiety-like behavior. Finally, we performed NOR test. The recognition index was measured as the percentage of time the mice spent exploring the new object versus the time the animals spent exploring either object. Figure 2(d) indicates that the J20 Tg APPswInd mice treated with inhibitors of Wnt signaling displayed a significantly lower recognition index compared with the control mice. This is best evidenced in Fig. 2 (e), which shows that treated and control animals spent similar amounts of time exploring identical objects 1 and 2 in the familiarization phase, but in the testing phase, the treated Tg mice spent less time exploring the new object than the control mice did (Fig. 3f) . Thus, the treated Tg mice exhibited memory impairments in two different tests (MWM and NOR), indicating that dysfunctional Wnt signaling accelerates memory loss in the J20 APPswInd Tg mice.
Increased levels of the phosphorylated tau protein are observed in treated Tg mice Treatment of Tg mice with Wnt inhibitors increased the levels of active GSK-3b kinase, a key component of the Wnt signaling pathway. GSK-3b is also active in NFTs of AD patients (Pei et al. 1999) and has been demonstrated to phosphorylate the tau protein at most serine and threonine sites in paired helical filaments (PHFs) both in vitro and in vivo (Hooper et al. 2008; Mandelkow and Mandelkow 2012; Hernandez et al. 2013) . Therefore, we examined the effect of Wnt inhibitors on tau protein phosphorylation. First, we evaluated the T231 and S235 epitopes in the tau protein because these residues have been associated with inhibition of the binding of tau to microtubules and triggering the process of tau aggregation (Sengupta et al. 1998; Gong et al. 2005) . We observed that in Tg mice, both TI and AS treatment induced significant increases in the phosphorylation of the T231 and S235 epitopes (Fig. 3a) . In addition, we evaluated other epitopes using PHF1 and AT8 antibodies. PHF1 (phosphorylated S396 and S404) and AT8 (phosphorylated S202 and T205) epitopes can also be mediated by GSK-3b and, in AD, have been associated with the presence of PHFs and NFTs (Iqbal et al. 1989; Jicha et al. 1997; Zheng-Fischhofer et al. 1998) . In treated Tg mice, only treatment with AS induced a significant increase in phosphorylation of the AT8 sites; however, no significant differences were observed in the phosphorylation of the PHF1 epitopes (Fig. 3b) , suggesting that attenuation of the Wnt signaling pathway favors tau phosphorylation and may induce its dissociation and aggregation in neurons. In addition, we separated the soluble fraction from the hippocampus by boiling a crude extract of the hippocampal lysate for 5 min, followed by centrifugation at 20 000 g for 1 h. Ten micrograms of soluble proteins were then loaded on a slot-blot membrane and blotted with a phospho-S235 antibody. As shown in Fig. 3(c) , mice treated with the Wnt pathway inhibitors had higher levels of soluble, phosphorylated tau protein. Finally, to determine if Wnt inhibitors can trigger the formation of soluble oligomers of the tau protein, we resolved 50 lg of soluble protein on a Tris-Tricine gel, followed by blotting with the phospho-S235 antibody. As shown in Fig. 3(d) , a unique approximately 55-KDa band was observed, indicating that the phosphorylated tau protein did not aggregate to form soluble oligomers. Taken together, these results indicate that the attenuation of Wnt signaling induces the phosphorylation of the tau protein on different residues that could favor the destabilization of microtubules; however, tau oligomer formation was not detected. (Kuperstein et al. 2010) . We have previously demonstrated that the inhibition of the Wnt pathway favors amyloidogenic processing of APP, increasing Ab 1-42 production and the formation of low-n oligomers, such as trimers and tetramers, in CHO 7PA2 cells (Tapia-Rojas et al. 2016) . We therefore hypothesized that inhibition of Wnt signaling in vivo would also induce the formation of the Ab peptide. We measured the concentrations of the Ab 1-42 and Ab 1-40 peptides in hippocampal lysates from all experimental groups using ELISAs (Fig. 5ai and ii) and found that the Ab 1-42 concentration was higher in Tg APPswInd mice treated with the Wnt inhibitors (Fig. 4ai) . In addition, we evaluated the Ab 42 /Ab 40 ratio and observed a considerable increase in this ratio in the hippocampus in treated J20 Tg mice (Fig. 4aii) , strongly suggesting the presence of major toxicity in the brains of animals with altered Wnt signaling. According to the amyloid hypothesis, the increase in the Ab concentration is the result of an imbalance between Ab production and clearance or transport across the blood-brain barrier (BBB), coupled with a decrease in Ab proteolytic degradation (Bates et al. 2009 ). In AD patients, the decrease in the Ab 1-42 concentration in the CSF is accompanied by an increase in Ab levels in the CNS (Wiltfang et al. 2001 (Wiltfang et al. , 2002 . We therefore extracted CSF from the cisterna magna of the control and treated mice and measured Ab 1-42 levels by ELISA. The Ab 1-42 concentration in the CSF was drastically lower in all treated groups than in the control Tg mice (Fig. 4aiii) . These results indicate that Ab 1-42 peptide accumulates in the hippocampus of treated mice, and suggest that attenuation of Wnt signaling could reduce the clearance of Ab and/or accelerate its production in the brain in J20 Tg mice treated in the presymptomatic stages such as previously described in vitro (Tapia-Rojas et al. 2016).
Attenuation of Wnt signaling increases the levels of soluble Ab oligomers
The increase in the Ab concentration in the brains of animals with alterations in Wnt signaling may be because of overproduction of Ab or impaired clearance from the brain, as indicated by the decrease in the Ab 1-42 concentration in the CSF (Fig. 4a) . Clearance can be reduced by a variety of factors, including increased aggregation, defective degradation, disturbed balance of transport across the BBB, or inefficient peripheral removal of the peptide (Kurz and Perneczky 2011) . To evaluate the hypothesis that Ab exhibits increased aggregation, we separated the soluble fraction from the hippocampus, loaded 6 lg of soluble proteins on a slotblot membrane, and performed a western blot with the 6E10 antibody. As shown in Fig. 4(b) , mice treated with the Wnt pathway inhibitors exhibited higher levels of soluble species of Ab; all administered treatments increased the levels of Ab oligomers in J20 Tg mice. To identify the soluble species of Ab present in the hippocampus of treated mice, 100 lg of soluble proteins was resolved on Tris-Tricine gels and subjected to western blotting with the 6E10 antibody. As shown in Fig. 4(c) , we observed two important species of Ab, an approximately 26-KDa band, potentially corresponding to hexamers, and an approximately 55-KDa band, potentially representing high-molecular-weight oligomers of Ab (dodecamers) (Lesne et al. 2006; Klein 2012; Lesn e et al. 2013) . Only TI treatment in the Tg mice induced a significant increase in the levels of the approximately 26-KDa low-n oligomer (Fig. 4c) . Subsequent evaluation of the presence of high-molecular-weight oligomers via a slot-blot assay using the A11 antibody, which binds to a specific oligomeric conformation (Lesne et al. 2006) , revealed that AS-treated Tg mice exhibited higher levels of this species compared with the control Tg mice (Fig. 4d) . To confirm that the oligomers detected by the A11 antibody corresponded to the previously described species (Lesne et al. 2006 ), we performed a western blot and observed that the antibody effectively detected an approximately 56-KDa band (Fig. 4e) . Together, these results indicate that dysfunctional Wnt signaling accelerates the production and aggregation of Ab in J20 Tg mice treated in the pre-symptomatic stages. Finally, we measured the levels of total APP. Figure 4 (f) indicates that both the TI and AS treatments reduced APP levels in J20 Tg mice, suggesting that APP can be proteolytically processed by the amyloidogenic pathway in Tg animals with alterations in Wnt signaling and might explain the increase in the Ab peptide concentration and its aggregation in the brain.
Inhibition of canonical Wnt signaling increases the number and size of senile plaques in J20 Tg mice
The Ab peptide can aggregate to form low-n oligomers, and further aggregation results in the formation of fibrillar structures known as SPs, a hallmark of AD (Masters and Selkoe 2012) . We next evaluated the presence of Ab plaques in the brains of treated and control mice. Cortical and hippocampal tissues were analyzed by Th-S staining. Th-Spositive staining was observed in sections from both control and treated J20 Tg mice (Fig. 5a) . Digital quantification and analysis of the treated Tg mice compared with the control Tg mice revealed that the hippocampus of the AS-treated mice displayed an increase in the area occupied by amyloid deposits, in contrast to TI treatment that show similar area with the control animals (Fig. 5b) ; and both the TI and AS treatments increased the percentage of positively stained area of SPs in the cortex (Fig. 5c ). In addition, a cumulative plot of Ab plaque size (Fig. 5d) revealed that the TI-treated mice had larger SPs (Fig. 5d , dark gray line) than the Tg control animals (Fig. 5d, black line) . In contrast, the AS-treated animals exhibited smaller plaques in the hippocampus and cortex compared to the control Tg mice (Fig. 5d, gray line) . These results suggest that the inhibition of Wnt signaling in Tg mice accelerated the development of amyloid plaques by altering their number and size, suggesting that the amyloid pathology is exacerbated.
Overall, these results demonstrate that Wnt signaling plays a role in the pathogenesis of AD; in particular, inhibition of the Wnt signaling pathway accelerates the development of AD in J20 Tg mice.
Treatment with Wnt signaling inhibitors also triggers dysfunction of the Wnt signaling pathway, phosphorylation of tau protein, and increased production of Ab 1-42 in WT mice We have previously demonstrated that factors such as an Lmethionine-enriched diet in WT mice cause neurotoxic effects in vivo, including dysfunction of the Wnt signaling pathway, that contribute to Alzheimer's-like neurodegeneration (Tapia-Rojas et al. 2015b) . For this reason, we also treated 3-month-old WT mice with vehicle, TI, AS, or IWP-2, a compound that inactivates the porcupine enzyme and inhibits Wnt ligand palmitoylation and secretion, indicated here as 'Wnt inhibitor' (WI) (Chen et al. 2009 ), for 10 weeks. In WT mice, we decided also treat the animals with WI to evaluate whether repressing the secretion of either canonical or non-canonical Wnt ligands, the pathological phenotype AD-associated could be more severe compared to only canonical Wnt signaling inhibition treatment. Western blot performed on hippocampal lysates revealed an increase in the levels of GSK-3b phospho-Tyr216, the active form of GSK-3b, and in the phosphorylated form of b-catenin at Ser33, Ser37, and Thr41 with TI, AS, and WI treatment (Fig. 6a) . In contrast, the levels of both c-jun and cyclin D-1, target genes of the Wnt pathway, were decreased in WT mice following treatment (Fig. 6b) . When we evaluated the levels of other key Wnt components, we observed that the levels of Wnt-7a and Wnt-3a were lower in the treated WT mice (Fig. 6c ) than untreated mice, whereas the levels of Wnt-5a, a non-canonical Wnt ligand, were lower only in the WT mice treated with WI (Fig. 6c) . In addition, the levels of Dkk-1 as well as sFRP-1 were significantly higher in the treated WT mice (Fig. 6d) , as opposed to the levels of sFRP-2, which were significantly lower in WT mice exposed to Wnt inhibitors (Fig. 6d) . Altogether, these results indicate that Wnt signaling inhibitors administered to WT mice induced alterations in its components, triggering a dysfunction of the pathway. These animals were also evaluated for the presence of different epitopes of tau protein phosphorylation. We measured the T231 and S235 epitopes and observed a significant increase in phosphorylation of the T231 site in WT mice for all treatments, but only the AS and WI drugs induced an increase in the levels of phosphorylated S235 (Fig. 7a) . In addition, we evaluated other epitopes using PHF1 and AT8 antibodies and found that AS and WI but not TI increased the levels of phospho-AT8, whereas all treatments increased phosphorylation at the sites recognized by the PHF1 antibody (Fig. 7b) . Therefore, our results indicate that attenuation of the Wnt signaling pathway induced tau protein phosphorylation in WT mice. We also analyzed the levels of Ab in the hippocampus of control and treated WT mice. For this purpose, we first measured the concentrations of the Ab peptide in the hippocampus from WT animals and compared it with that in J20 Tg mice using ELISAs (Fig. 7c and d) . As we expected, the Ab 1-42 concentration was significantly higher in the J20 Tg mice than in the WT mice (Fig. 7c) , however, the levels were~5-fold more higher. These results suggest that J20 Tg mice are in the initial stage of the Ab pathology, because at 10 month-old or more the differences are significantly higher (Cheng et al. 2004; Roberson et al. 2007; Fabbro et al. 2011) . We evaluated the Ab 42 /Ab 40 ratio in control WT and J20 Tg mice and observed a drastic increase in this ratio in the hippocampus of control Tg mice (Fig. 7d) , confirming the presence of major toxicity in the brain of Tg mice compared with WT animals. However, the results also indicate that the WT mice had detectable levels of Ab 1-42 in the hippocampus. Consistently, a significant amount of soluble Ab species in the brain of J20 Tg mice was observed in the slot-blot assay revealed with the 6E10 antibody (Fig. 7e) , and higher levels of Ab oligomers were detected with the A11 antibody in the hippocampus of Tg animals in comparison with WT mice (Fig. 7e) . These results show that J20 Tg mice produce more Ab than WT animals do but also indicate that the levels of Ab in WT mice can be detected using this experimental approach. Then, we measured the concentrations of the Ab 1-42 and Ab 1-40 peptides in hippocampal lysates of control and treated WT animals using ELISAs ( Fig. 7f and g ). The Ab 1-42 concentration was increased in WT mice treated with all Wnt inhibitors tested (Fig. 7f) . In addition, we evaluated the Ab 42 /Ab 40 ratio and observed an important increase in this ratio in the hippocampus in treated WT mice (Fig. 7g) , suggesting a major toxicity in the hippocampus of animals with altered Wnt signaling. When we measured the Ab 1-42 concentration in the CSF, we observed a drastic decrease in all treated groups compared with that in control WT mice (Fig. 7h) . These results suggest that attenuation of Wnt signaling induces the production of Ab in the brain and/or reduces Ab clearance toward the CSF in WT mice. Finally, we measured the levels of soluble Ab species with the 6E10 antibody using a slot-blot assay and observed that only AS and WI treatment increased the amount of Ab (Fig. 7i) , whereas the levels of Ab revealed with the A11 antibody were increased in all treated experimental groups, suggesting that inhibition of Wnt signaling in WT mice increased the amount of soluble Ab species, possibly as a consequence of increased Ab formation.
Dysfunction of Wnt signaling impairs learning and memory in WT Tg mice
Wnt signaling contributes to the development of hippocampal memory (Tabatadze et al. 2012; Fortress et al. 2013) . To evaluate whether dysfunction of Wnt signaling alters the behavioral functions of the hippocampus in WT mice, we subjected the animals to the MWM and NOR tasks. In the MWM test, WT mice treated with Wnt inhibitors exhibited higher escape latency values compared with WT controls injected with vehicle solution, as indicated by the swim tracks shown in Fig. 8(a) and (b) . These differences were significant during the first week of training and were more evident during the second week, suggesting impairments in both the learning and memory processes. No significant differences in the escape latency were observed between the treated groups (Fig. 8b) . Furthermore, no significant differences in swimming speed were observed, indicating normal locomotor activity in all experimental groups (Table S2) . When we performed the visible platform version of the MWM test, a similar escape latency was observed between control and treated animals (Fig. 8c) , indicating that the observed results were specifically associated with hippocampal function. In addition, Figure S2 shows that treated WT animals did not exhibit any significant differences in the OF test (Figure S2 ), eliminating the influence of anxiety-like behavior. Finally, we performed the NOR test, and as shown in Fig. 8(d) , the treated WT mice spent less time exploring the new object compared with the control WT mice in the testing phase. The difference was even more evident when we evaluated the recognition index, which indicate that the WT mice treated with Wnt inhibitors displayed a significantly lower recognition index compared with the control mice. Thus, the treated WT mice exhibited learning and memory impairment, indicating that attenuation of Wnt signaling triggered a loss in cognitive abilities in WT mice. In summary, our results indicate that the dysfunction of Wnt signaling induced an AD-like neuropathology in WT mice.
Discussion
In this study, animals treated with Wnt signaling inhibitors exhibited (i) alterations in the levels of Wnt pathway components; (ii) cognitive deficits hippocampus-dependent; (iii) increased tau phosphorylation; (iv) increased Ab 1-42 peptide concentrations and Ab42/Ab40 ratio in the hippocampus; (v) decreased Ab 1-42 concentration in the CSF; (vi) higher levels of soluble Ab species and synaptotoxic oligomers and (vii) an altered amount and size of SPs in Tg mice. Together, these data indicate that inhibition of the Wnt signaling pathway may be a triggering factor for the pathogenesis of AD that exacerbates the pathology in the J20 Tg APPswInd mouse model of AD and contributes to the development of AD-like alterations in WT mice.
Canonical Wnt signaling is active when the Wnt ligand binds to the Fz-LRP6 receptor. GSK-3b is subsequently inhibited, and b-catenin accumulates and translocates to the nucleus, where it interacts with TCF/LEF transcription factors to initiate Wnt target gene transcription (Nusse 2012; Inestrosa and Varela-Nallar 2014) . In this study, we treated WT and J20 Tg mice with vehicle, a TI (Emami et al. 2004) , an AS (Huang et al. 2009 ), or WI, which inhibits Wnt palmitoylation and secretion (Chen et al. 2009 ). These treatments triggered serious alterations in key components of the canonical Wnt pathway, such as an increase in phosphorylated b-catenin and GSK-3b activity. The stabilization and nuclear translocation of b-catenin are two characteristics of canonical Wnt signaling (Clevers and Nusse 2012) necessary for the final function of the pathway (Cadigan and Waterman 2012; Jamieson et al. 2012) . The expression of the Wnt target genes, c-jun and cyclin-D1, were decreased, indicating deficient Wnt signaling. Interestingly, we also observed altered expression of other proteins important, such as the Wnt-7a and Wnt-3a ligands, the antagonists' sFRP-1, Dkk-1, and sFRP-2. WI treatment also induced a decrease in the levels of the Wnt-5a ligand in WT mice.
The activation of canonical or non-canonical Wnt signaling depends on the cellular context and ligand-receptor binding and is not dependent on the ligand itself (Mikels and Nusse 2006; Grumolato et al. 2010) . However, Wnt ligands have classically been classified as activators of the canonical or the non-canonical pathway. Wnt5a is agonists of the noncanonical pathway, whereas Wnt3a and Wnt7a/b are considered ligands of the canonical pathway (Gordon and Nusse 2006; MacDonald et al. 2009; Kikuchi et al. 2011) . Wnt ligands have important functions in the adult brain. Wnt-7a increases the clustering of the synapsin I (Lucas and Salinas 1997; Hall et al. 2000) and the number of pre-synaptic sites, induces neurotransmitter release (Cerpa et al. 2008) and improves the clustering of the a7-nACh receptor (Farias et al. 2007) , regulating pre-synaptic structure. In addition, Wnt-7a increases the density and maturity of dendritic spines (Ciani et al. 2011) , and is released after the MWM test (Tabatadze et al. 2012) ; suggesting a role in memory formation. Wnt-3a release facilitates the LTP process; suggesting that Wnt-3a plays a role in synaptic plasticity. Synaptic failure is an early event in AD pathology (Terry et al. 1991; Selkoe 2002; Pozueta et al. 2012) ; therefore, the decreases of Wnts in the hippocampus of mice treated with Wnt inhibitors may be a key event in the neuronal dysfunction. In contrast, Wnt-5a activates non-canonical Wnt signaling (Farias et al. 2009; Cuitino et al. 2010) , modulates post-synaptic assembly and function (Farias et al. 2009 ), modulates spine formation (Varela-Nallar et al. 2010) and facilitates LTP (Cerpa et al. 2011) . Here, WI-treated WT mice exhibited a decrease in the Wnt-5a ligand, suggesting a loss of functions in the post-synaptic region. These alterations, coupled with the changes observed in the ligands Wnt-7a and Wnt-3a, may suggest a more aggressive AD-like pathology in this experimental group. sFRPs are antagonists of Wnt signaling (Jones and Jomary 2002) able to compete with Fz receptors for Wnt ligands. sFRP-1 have important roles in the adult brain (Trevant et al. 2008) , such as blocking dendritic development (Rosso et al. 2005) . Up-regulation of sFRP-1 has also been associated with brain tumors (Lee et al. 2003) . Treated WT and Tg mice displayed a drastic increase in the levels of the sFRP-1 protein, suggesting that sFRP-1 antagonizes Wnt signaling and could contributes to the damage of neuronal cells. Moreover, sFRP-2 acts as a synergistic activator of the canonical Wnt pathway (Kress et al. 2009 ). sFRP-2 enhances Wnt3a-dependent LRP6 phosphorylation and increases transcriptional activity of b-catenin (von Marschall and Fisher 2010) . In this study, the treated mice exhibited low levels of sFRP-2 in the hippocampus, suggesting that in addition to decreases in Wnt-3a levels, decreases in sFRP-2 levels further may contribute to dysfunction of the canonical Wnt pathway. Finally, we also observed a significant increase in Dkk-1 protein levels in the hippocampus in treated mice. Dkk inhibits Wnt pathway by binding to the LRP5/6 co-receptor and promoting its endocytosis and subsequent degradation (Ahn et al. 2011) . Dkk-1 expression is increased favoring toxicity (Caricasole et al. 2004; Cappuccio et al. 2005; Rosi et al. 2010) , inducing tau phosphorylation and neuronal death (Scali et al. 2006) . Synaptic failure is an early event in AD and Dkk-1 is required for Ab-mediated synaptic loss (Purro et al. 2012) ; therefore, the increased Dkk-1 levels observed in Tg and WT mice could be relevant to the neurotoxicity generated by Ab in the hippocampus. Taken together, the observed changes in key Wnt signaling components suggest drastic alterations of brain Wnt signaling function.
The purpose of our study was to evaluate the effects of the attenuation of the Wnt pathway on brain function and the neuropathological hallmarks of AD. According to the amyloid cascade, AD begins when the Ab peptide is generated from APP cleavage by b-and c-secretase by the amyloidogenic processing (De Strooper et al. 2010) . The factor(s) that trigger this amyloidogenic APP processing are unknown. We have demonstrated in vitro that Wnt signaling activity directly modulates APP processing and Ab production. Inhibition of the Wnt pathway favors amyloidogenic APP cleavage, Ab 42 generation, and Ab oligomer formation (Tapia-Rojas et al. 2016) . Here, we demonstrated that inhibition of Wnt signaling accelerates Ab accumulation in the hippocampus of J20 Tg mice and induces Ab production in the hippocampus of WT mice. Additional studies are required to determine the mechanisms by which Wnt signaling inhibition triggers Ab production in vivo. APP processing generates Ab peptides that differ in length at their carboxy termini (Sato et al. 2003; Qi-Takahara et al. 2005; Kakuda et al. 2006) . The concentrations of Ab 1-42 depend on the imprecise processing of APP by the c-secretase complex (Pauwels et al. 2011) . Ab 1-42 is highly fibrillogenic, has fast aggregation kinetics, and is prone to form neurotoxic aggregates (Chen and Glabe 2006) . In this study, we reported that the inhibition of Wnt signaling in both WT and Tg mice in vivo increased the concentration of the Ab 1-42 peptide. Moreover, we also evaluated the Ab42/Ab40 ratio in the brains of the experimental groups and reported an increase in the ratio in the hippocampus of the treated WT and Tg mice, strongly suggesting higher toxicity in the hippocampus in these animals. In fact, an increased Ab42/ Ab40 ratio has been directly associated with more aggressive forms of the disease (Hellstrom-Lindahl et al. 2009 ). The amyloid hypothesis states that AD originates from an imbalance between Ab production and clearance; therefore, decreased catabolism of Ab, reduced efflux from the brain across the BBB, or impaired CSF transport can alternatively result in increased concentrations of Ab in the brain and promote its aggregation. In FAD, mutations increase Ab production. However, in sporadic AD, Ab deposition may also be produced by deficient clearance (Hardy and Selkoe 2002) . In the treated mice, the concentration of Ab 1-42 in the CSF was decreased, suggesting altered clearance of Ab and potentially explaining the higher Ab levels observed in the hippocampus of the treated animals. Another possibility is a reduced efflux from the brain across the BBB, which have been associated with AD (Honjo et al. 2012; Luissint et al. 2012 ). An increase in the activity of influx versus efflux within the BBB has been suggested to contribute to the accumulation and deposition of Ab in the brain (Deane et al. 2009 ). In addition Ab deposition impedes its diffusion to the CSF, explaining the reduced Ab concentration in the CSF (Strozyk et al. 2003) . Wnt signaling can maintain and even restore the BBB properties (Lim et al. 2008; Daneman et al. 2009; Kania et al. 2011; Paolinelli et al. 2013; Shen et al. 2013) . Therefore, the loss of the Wnt pathway observed in treated animals may decrease Ab clearance across the BBB, future studies are required to validate this hypothesis.
Ab peptides are present as monomers but also have the capacity to aggregate to form oligomers and insoluble fibrils or SPs, mainly in the cortex and hippocampus (Mucke and Selkoe 2012) . The Ab42/Ab40 ratio was higher in treated mice than in control mice, and even small changes in the Ab42/Ab40 ratio favor the formation of Ab oligomers (Yoshiike et al. 2003; Kuperstein et al. 2010) . Treatment with Wnt inhibitors favored the formation of oligomers, suggesting the presence of hexamers and synaptotoxic, 56-KDa species (Lesne et al. 2006; Lesn e et al. 2013) . The reduced CSF concentration of Ab 1-42 in AD has been hypothesized to be caused by the deposition of peptides in SPs, which results in the diffusion of lower levels to the CSF. An autopsy study observed a correlation between low Ab 1-42 levels in the CSF and increased numbers of SPs in the cortex and hippocampus (Strozyk et al. 2003) . In the treated Tg mice, we observed a larger number of SPs of different sizes compared with the Tg control mice, validating this hypothesis. In contrast, SPs were not detected in the brains of WT mice. However, the severity of the AD pathology correlates with soluble species of Ab rather than the SPs present in the brain (McLean et al. 1999) ; therefore, the results observed in WT mice might also be important for elucidating the neurodegenerative process.
High levels of Ab initiate a cascade of events that include tau phosphorylation, synaptic alterations, and learning and memory deficits, culminating in a progressive clinical dementia of the Alzheimer's type (Barage and Sonawane 2015; Musiek and Holtzman 2015) . Inhibition of Wnt signaling has been proposed to favor GSK-3b-mediated tau hyperphosphorylation (Scali et al. 2006; Hooper et al. 2008) . GSK-3b phosphorylates the tau protein at nearly all sites at which the tau protein has been modified in AD (Kremer et al. 2011; Hernandez et al. 2013) . Conditional Tg mice that over-express GSK-3b during adulthood exhibit decreased nuclear b-catenin levels, tau hyperphosphorylation and neurodegeneration (Lucas et al. 2001) , and chronic lithium treatment prevents NFT formation in a double Tg mouse over-expressing GSK-3 and tau (Engel et al. 2006) . Because GSK-3b activity is directly regulated by the activation of Wnt signaling, the loss of the Wnt pathway is a relevant negative effector in this hallmark of AD. Interestingly, in both the treated Tg and WT mice, phosphorylation at the T231 and S235 epitopes of the tau protein was increased. Phosphorylation at the PHF1 and AT8 epitopes was also increased in the treated WT mice, whereas in the Tg mice, PHF1 phosphorylation was unaffected. T231 and S235 have been associated with the process triggering tau aggregation into NFTs (Sengupta et al. 1998) . In contrast, AT8 and PHF1 are associated with the process of aggregation and accumulation of PHFs, which form NFTs and are conformation-dependent (Zheng-Fischhofer et al. 1998; Mandelkow and Mandelkow 2012) . These results indicate that Wnt signaling loss deregulates tau kinases such as GSK-3b and, thus, favors the dissociation of tau protein from the microtubules, an initial process in the early stage of AD.
The Ab peptide or phosphorylated tau protein present in the brain ultimately lead to synaptic dysfunction and cognitive impairments . Wnt signaling plays key roles in synaptic plasticity (Farias et al. 2007; Cerpa et al. 2008) , regulating the release of neurotransmitters that favor synaptic transmission (Speese and Budnik 2007; Oliva et al. 2013) , inducing the LTP process (Hooper et al. 2007; Peineau et al. 2007 ) and inhibiting LTD (Peineau et al. 2007) , the two main processes involved in memory formation. Wnt signaling also stimulates the transcription of Wnt target genes required for long-term memory, such as calcium/calmodulin-dependent protein kinase type IV (Arrazola et al. 2009 ). In this study, inhibition of Wnt signaling triggered severe defects in learning and memory in WT mice and J20 Tg APPswInd mice at a stage in which cognitive impairment was not yet evident using two different tests, because J20 Tg mice show spatial learning and memory deficits beginning at 6-7 month-old (Palop et al. 2003; Galvan et al. 2006; Roberson et al. 2007 ). Thus we confirm the importance of Wnt signaling in spatial and recognition memory associated with hippocampal function. This result is in agreement with previous studies demonstrating that spatial memory increases the levels of the Wnt ligands in the hippocampus (Tabatadze et al. 2012) and that the Wnt pathway is required for object recognition memory consolidation (Fortress et al. 2013) .
In this work, we used different Wnt inhibitors that act in distinct steps in the signaling: TI, AS, and WI. Interestingly, these treatments yielded distinct results. Inhibition of the bcatenin-dependent gene transcripts was sufficient to induce severe alterations in the levels of the Ab 1-42 peptide and synaptotoxic oligomers of Ab and in cognitive function, which is indicative of the relevance of Wnt target genes in the function of the hippocampus and in the toxicity associated with AD. However, the TI drug did not induce significant changes in some of the hallmarks associated with AD that were analyzed here, such as the area occupied by SPs in the hippocampus of the Tg mice and in the phosphorylation of tau protein in both WT and Tg mice. These results are also evidence of the key role of GSK-3b in these processes because the AS treatment, which acts downstream of GSK-3b kinase, produced more significant alterations than the TI treatment. In addition, a more aggressive phenotype of AD-like neuropathology was observed in the WI-treated WT mice because the porcupine enzyme is required for the post-translational modification of all Wnt ligands to enable their secretion and activity (Proffitt and Virshup 2012) . Therefore, the inhibition of porcupine might inhibit the function of other Wnt ligands, such as Wnt5a. WI treatment decreased the levels of the Wnt-5a protein in the WT mice. Our laboratory has described roles of Wnt5a in the post-synaptic region and in synaptic plasticity (Inestrosa and Arenas 2010; Vargas et al. 2014) ; thus, the attenuation of these functions may also contribute to the more severe alterations observed in the WI-treated WT mice. Interestingly, only the WI treatment reduced total APP levels, suggesting that another Wnt ligand may have a role in APP processing and/or degradation in vivo.
In 1999, our laboratory proposed for first time an association of the deregulation of Wnt pathway with AD, and since then the studies in the area have increased. We and other groups have proposed, studied and summarized the hypothesis that a loss of Wnt signaling could play a role in the onset and progression of AD (De Ferrari et al. 2014; Inestrosa and Varela-Nallar 2014) . In fact, a variety of studies have demonstrated the neuroprotective function of the Wnt signaling pathway against the toxicity of the Ab peptide (De Ferrari et al. 2003; Alvarez et al. 2004 ) through Wnt-3a-Fz1 receptor binding (Chacon et al. 2008) or inducing to the repressor element 1-silencing transcription factor to preserve cognitive functions (Lu et al. 2014 ). In addition, in a double-Tg APPswe/PSEN1DE9 mouse model of AD, the activation of Wnt signaling by lithium or andrographolide reduces spatial memory impairments, decreases astrogliosis, and decreases the levels of Ab aggregates and oligomers (Toledo and Inestrosa 2010; Serrano et al. 2014) . Similarly, in a triple transgenic AD mice (3 9 Tg-AD), the activation of canonical Wnt pathway with sodium selenate reduce tau phosphorylation, ameliorate Ab 1-42 formation, and inhibit apoptosis (Jin et al. 2017) . In contrast and interestingly, in our study we demonstrated for first time that inhibition of the Wnt pathway in a Tg mouse model of AD at pre-symptomatic stages accelerated the initiation and development of the pathology. More important, in WT mice, the attenuation of canonical Wnt signaling triggered a neurodegenerative process that involves the production and aggregation of Ab, tau phosphorylation and cognitive impairment. In conclusion, our findings show in a unique study that dysfunction of Wnt signaling is sufficient to accelerate the onset of disease in Tg APPswInd AD mice and induces AD-like neurodegeneration in WT mice, favoring the appearance of AD hallmarks and finally a memory loss. Together, these results strongly suggest that the loss of the canonical Wnt pathway could be considered a triggering factor for AD.
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